Edition:
United States

Profile: Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

2.23USD
22 Sep 2017
Change (% chg)

$-0.03 (-1.33%)
Prev Close
$2.26
Open
$2.25
Day's High
$2.28
Day's Low
$2.20
Volume
144,134
Avg. Vol
173,472
52-wk High
$3.31
52-wk Low
$1.30

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Company Address

Idera Pharmaceuticals Inc

167 Sidney St
CAMBRIDGE   MA   02139-4237
P: +1617.6795500
F: +1617.6795592

Company Web Links